About the Project
A long-standing and ongoing fundamental challenge in cross-coupling chemistry is the formation of stereodefined carbon-carbon bonds using Csp3-Csp2 Suzuki-Miyaura cross-coupling.[1,2] Secondary, enantiopure alkyl boron reagents are readily accessible, bench-stable and configurationally stable, and thus can be considered as the ideal cross-coupling partners – the pre-installed stereochemistry can be perfectly translated into the targeted products. However, whilst there have been notable stereospecific Suzuki-Miyaura cross-coupling successes with acyclic alkyl boron reagents,[3-5] the analogous reactions with cyclic systems have been far more challenging to develop[4,5] – and this topic will be directly addressed in this project, with the focus on 3-D pharmaceutically-relevant saturated nitrogen and oxygen heterocycles.
1. To use automated high throughput experimentation and rich data analysis to optimise conditions for Csp3-Csp2 cross-coupling of saturated heterocyclic boronates
2. To explore the scope and limitations of the cross-coupling methodology
3. To apply the methodology to targets of relevance to medicinal chemistry, including covid-19 proteins
In this project which will be carried out in collaboration with GlaxoSmithKline, we will synthesise bench-stable, stereodefined, enantiopure heterocyclic alkyl boronate building blocks and deploy them in stereospecific Csp3-Csp2 Suzuki-Miyaura cross-coupling reactions. The pharmaceutical industry has specifically highlighted the need for a general stereoselective method: “With the success of the Suzuki-Miyaura coupling reaction in generating biaryl motifs, a variant allowing routine sp3–sp2 and sp3–sp3 couplings – ideally in an enantioselective manner – is both highly desirable and could fundamentally change the motifs being generated.” This is one of the last remaining problems to solve in cross-coupling chemistry – it is our conjecture that the key to unlocking the potential of such reactions is a combination of high throughput experimentation, statistical analysis of rich data and in-depth mechanistic studies. Reaction discovery and optimisation of suitable catalytic protocols will be driven by automated high throughput experimentation, rich data analysis and rigorous mechanistic studies. Given the ubiquity of cyclic molecules containing stereodefined Csp3-Csp2 bonds in FDA-approved drugs, the process could become an enabling and transformative technology for use within medicinal chemistry programmes. The methods will also be used for the synthesis of libraries of elaborated fragments from fragment hits generated against covid-19 proteins.[7,8]
There is currently no method for the general stereospecific Csp3-Csp2 Suzuki-Miyaura cross-coupling of enantiopure saturated heterocyclic boronates with aryl halides. This project aims to deliver such a process to enable non-traditional disconnections, fundamentally changing the way that three-dimensional saturated nitrogen and oxygen heterocycles can be constructed.
This project will provide state-of-the-art training in modern synthetic methodology and medicinal chemistry, including a placement at GlaxoSmithKline. The graduating PhD student will be fully equipped for a future career in the pharmaceutical industry. All Chemistry research students have access to our innovative Doctoral Training in Chemistry (iDTC): cohort-based training to support the development of scientific, transferable and employability skills.
The Department of Chemistry holds an Athena SWAN Gold Award and is committed to supporting equality and diversity for all staff and students. The Department strives to provide a working environment which allows all staff and students to contribute fully, to flourish, and to excel: https://www.york.ac.uk/chemistry/ed/.
You should hold or expect to achieve the equivalent of at least a UK upper second class degree in Chemistry or a related subject. Please check the entry requirements for your country: https://www.york.ac.uk/study/international/your-country/
For more information about the project, click on the supervisor's name above to email the supervisor. For more information about the application process or funding, please click on email institution
This PhD will formally start on 1 October 2021. Induction activities will start on 27 September.
Tax-free annual “UKRI level” stipend (£15,285 full time for 2020/21)
UK tuition fees (£4,473 for 2021/22)
Research support and training charges
International candidates (including EU) may be considered, however the fee difference would need to be covered from other sources. International tuition fees for 2021 entry are £22,250
2. Rygus, J. P. G.; Crudden, C. M. J. Am. Chem. Soc. 2017, 139, 18124.
3. Crudden, C. M. et al. J. Am. Chem. Soc. 2009, 131, 5024.
4. Sigman, M. S.; Biscoe, M. R. et al. Science 2018, 362, 670.
5. Burke, M. D. et al. Nat. Commun. 2019, 10, 1263.
6. Blakemore, D. C. et al. A. Nat. Chem. 2018, 10, 383.
Based on your current searches we recommend the following search filters.
Based on your current search criteria we thought you might be interested in these.